Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic HCV infection at Screening.~2. Screening laboratory result indicating HCV genotype 1b infection.~3. Treatment-naïve and non-cirrhotic.~Exclusion Criteria:~1. HCV genotype or subtype other than GT1b.~2. Positive test result for Hepatitis B surface antigen (HbsAg) or confirmed positive anti-HIV antibody (HIV Ab) test.~3. Any current or past clinical evidence of cirrhosis.~4. Screening laboratory analyses that shows abnormal results.~5. Clinically significant abnormalities or co-morbidities, other than HCV infection that make the participant an unsuitable candidate for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (Type: EXPERIMENTAL): Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).